-
Jun 21, 2008CUDC-305 meets key preclinical criteria for advancement
CAMBRIDGE, Mass., Jul 21, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of targeted small molecule drug...
-
Jun 2, 2008
CAMBRIDGE, Mass., Jun 02, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop the next generation of proprietary targeted medicines for...
-
May 12, 2008
CAMBRIDGE, Mass., May 12, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer...
-
May 5, 2008Trial tests oral administration of GDC-0449 in combination with bevacizumab and a standard chemotherapy regimen
CAMBRIDGE, Mass., May 05, 2008 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer...
-
Apr 29, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 30, 2008--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop the next generation of targeted medicines for cancer...